Research · head to head
Form Bio vs Genedata
Form Bio
Research
Computational platform for cell and gene therapy design and manufacturability
- From
- On request
- Rated
- -
Genedata
Research
Enterprise R&D data platforms for biologics, screening and bioprocess, owned by Danaher
- From
- On request
- Rated
- -
The short version
- Each has a real cost: Form Bio the company has pivoted twice since spinning out of Colossal Biosciences in 2022, from general computational life sciences to cell and gene therapy and then to AAV manufacturability, so any evaluation more than a year old describes a product that is no longer the commercial focus.; Genedata there is no entry level and no published price at any tier, so a mid-sized biotech cannot even establish whether Genedata is in its range without a lengthy sales engagement.
- They diverge on capability: Form Bio covers FormManufacturing, Genedata covers Screener.
- Prices and features above were last checked on 31 August 2026.
Where they differ
Only the attributes on which Form Bio and Genedata actually diverge.
Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).
What each one covers
Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.
Only in Form Bio
- FormManufacturing
- Payload design optimisation
- Genome integrity analysis
- Manufacturability prediction
- In silico workflows
- Scale-up monitoring
- Cell and gene therapy focus
- Collaboration
Only in Genedata
- Screener
- Biologics
- Bioprocess
- Expressionist
- Selector
- Profiler
- Instrument integration
- GxP-capable deployments
What people use each for
The jobs each tool is most often brought in to do.
Form Bio
- A gene therapy developer discovering manufacturability problems with an AAV construct late in process development and wanting to move that analysis earliernot Genedata
- A biotech comparing several candidate payload designs in silico before committing to expensive production runsnot Genedata
- A CDMO characterising what a client construct actually produces against what was specifiednot Genedata
- A programme team needing genome integrity evidence to support regulatory conversations about product consistencynot Genedata
Genedata
- A pharmaceutical screening group processing thousands of plates a week where manual QC and curve fitting no longer scalenot Form Bio
- A biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheetsnot Form Bio
- A process development group standardising bioprocess run data across sites for modelling and scale-upnot Form Bio
- A CRO delivering high-throughput screening results to sponsors that require documented, reproducible analysis pipelinesnot Form Bio
Where each one falls short
Documented limitations, not opinions. Every one is a constraint you would hit in normal use.
Form Bio
- The company has pivoted twice since spinning out of Colossal Biosciences in 2022, from general computational life sciences to cell and gene therapy and then to AAV manufacturability, so any evaluation more than a year old describes a product that is no longer the commercial focus.
- The current offering launched AAV-focused, so developers working in lentiviral, mRNA or cell therapy modalities are outside the scope the platform was built and validated for.
- No pricing is published and engagements are scoped per programme, which makes it impossible to size the commitment before entering a sales process.
- This is a young venture-funded company whose analyses feed regulatory-facing decisions, so continuity of the vendor over a multi-year development programme is a genuine diligence question rather than a formality.
- Predictive manufacturability models need real production data to be trustworthy, and the value depends on how much of that a young vendor has accumulated, which is difficult for a buyer to verify independently.
Genedata
- There is no entry level and no published price at any tier, so a mid-sized biotech cannot even establish whether Genedata is in its range without a lengthy sales engagement.
- Platforms are licensed individually and most organisations need two or three, so the real contract is a sum of separate licences plus the integration work between them.
- Deployment is a services programme rather than an installation, running months and requiring scientific configuration by the vendor, which means value arrives long after the first invoice.
- Danaher ownership since 2023 gives the roadmap a natural pull toward Danaher instrument and bioprocessing lines, which is an advantage on that hardware and a question to ask if your instrument estate is from competitors.
- Validated deployments for regulated use add scope, cost and an ongoing revalidation obligation on your side after each vendor release, and that recurring internal effort is rarely counted in the business case.
Pricing, plan by plan
Form Bio
On request- FormManufacturing$undefined/year
- Pricing only through a sales process
- Scoped per therapeutic programme rather than per seat
- AAV-focused offering at launch
Genedata
On request- Genedata platform licence$undefined/year
- Each platform, such as Screener or Biologics, licensed separately
- Annual enterprise subscription scoped on users, sites and data volume
- Implementation and scientific configuration services quoted as a separate programme
Which should you pick?
Choose Form Bio if
- You need formmanufacturing.
- You work on Web, Cloud.
- You also want payload design optimisation.
Choose Genedata if
- You need screener.
- You work on Web, On-premise, Private cloud.
- You also want biologics.
Questions people ask
- Is Form Bio or Genedata better?
- Neither clearly leads. Form Bio starts at On request and Genedata at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
- Which is cheaper, Form Bio or Genedata?
- Form Bio starts at On request and Genedata at On request.
- Does Form Bio or Genedata run on more platforms?
- Form Bio runs on Web, Cloud. Genedata runs on Web, On-premise, Private cloud.
- What is Form Bio best used for?
- Form Bio is most often used for a gene therapy developer discovering manufacturability problems with an aav construct late in process development and wanting to move that analysis earlier, a biotech comparing several candidate payload designs in silico before committing to expensive production runs, a cdmo characterising what a client construct actually produces against what was specified, a programme team needing genome integrity evidence to support regulatory conversations about product consistency. Of those, a gene therapy developer discovering manufacturability problems with an aav construct late in process development and wanting to move that analysis earlier and a biotech comparing several candidate payload designs in silico before committing to expensive production runs are not what Genedata is typically brought in for.
- What can Form Bio do that Genedata cannot?
- Form Bio covers FormManufacturing, Payload design optimisation, Genome integrity analysis, Manufacturability prediction. Genedata covers Screener, Biologics, Bioprocess, Expressionist.
Answered from the vendors’ own pages
Form Bio: What does Form Bio sell now?
FormManufacturing, launched in 2026, an AAV-focused platform for predicting, optimising and monitoring manufacturability of genetic medicines from construct design through scale-up.
Genedata: Who owns Genedata?
Danaher acquired the company in 2023. It remains headquartered in Basel and continues under the Genedata name.
Form Bio: Is it still a general bioinformatics platform?
No. It has narrowed from broad computational life sciences tooling to cell and gene therapy, and within that to AAV.
Genedata: Is there a small-team or starter option?
No. Everything is an enterprise contract scoped by users, sites and data volume, with services attached.
Form Bio: Where did the company come from?
It spun out of Colossal Biosciences in 2022.
Genedata: Do I buy one product or the whole suite?
Each platform is licensed separately. Most customers license two or three and integrate between them.
Form Bio: Is pricing published?
No. Engagements are scoped per programme through a sales process.
Genedata: Can it be used in a GxP environment?
Yes, with a validated deployment contracted as additional scope. Ongoing revalidation after releases remains your responsibility.
Related pages
Other head to heads
- Form Bio vs Benchling
- Form Bio vs DNAnexus
- Form Bio vs Dotmatics
- Form Bio vs Seven Bridges
- Form Bio vs Terra
- Form Bio vs OpenEye, Cadence Molecular Sciences
- Form Bio vs Schrodinger
- Form Bio vs Sapio Sciences
- Form Bio vs Mouseflow
- Form Bio vs Chemaxon
- Form Bio vs Labguru
- Form Bio vs Obsidian
- Form Bio vs Paperpile
- Form Bio vs Reduct
- Form Bio vs Remesh
- Form Bio vs Scispot
- Form Bio vs LabVantage
- Form Bio vs Medidata Rave
- Form Bio vs Castor EDC
- Form Bio vs Suzy
- Form Bio vs LabWare
- Form Bio vs Aurelius
- Form Bio vs TetraScience
- Form Bio vs Thermo SampleManager LIMS
- Form Bio vs Valispace
- Form Bio vs Wolfram Mathematica
- Genedata vs Benchling
- Genedata vs DNAnexus
- Genedata vs Dotmatics
- Genedata vs Seven Bridges
- Genedata vs Terra
- Genedata vs OpenEye, Cadence Molecular Sciences
- Genedata vs Schrodinger
- Genedata vs Sapio Sciences
- Genedata vs Mouseflow
- Genedata vs Chemaxon
- Genedata vs Labguru
- Genedata vs Obsidian
- Genedata vs Paperpile
- Genedata vs Reduct
- Genedata vs Remesh
- Genedata vs Scispot
- Genedata vs LabVantage
- Genedata vs Medidata Rave
- Genedata vs Castor EDC
- Genedata vs Suzy
- Genedata vs LabWare
- Genedata vs Aurelius
- Genedata vs TetraScience
- Genedata vs Thermo SampleManager LIMS
- Genedata vs Valispace
- Genedata vs Wolfram Mathematica